Alexandria Real Estate Equities, Inc. Announces Foundational Milestone in Mission-Critical Partnership with the Foundation for the National Institutes of Health to Advance Precision Medicine for Depression

Rhea-AI Summary

Alexandria Real Estate Equities (NYSE: ARE) announced a key milestone in its mission-critical partnership with the Foundation for the National Institutes of Health (FNIH): the Multi-Modal Assessment and Phenotyping in Depression (MAP-D) initiative has completed its critical design phase for a first-of-its-kind precision medicine clinical study in major depressive disorder.

Launched with Alexandria’s initial vision and funding, and its role as FNIH’s founding strategic partner, MAP-D aims to identify and validate biological signatures of depression to enable more personalized treatment and support development of more effective therapies. According to Alexandria, the long-term research effort is expected to exceed $70 million, beginning with a $22 million, three-year pilot phase. The study plans to use advanced AI models, generate one of the most comprehensive depression datasets to date, define biologically informed subtypes of depression, and make data broadly accessible to qualified researchers to accelerate scientific discovery in depression and other serious mental illnesses.

Market Context

ARE's partnership-tagged history recorded an average move of 0.05% across three events. That record ...

Analysis

ARE's partnership-tagged history recorded an average move of 0.05% across three events. That record frames MAP-D as a mission-oriented milestone rather than a demonstrated financial catalyst; net buying insider sentiment provides supportive context, while historical divergence remains a risk.

Key Figures

Adults affected: more than 21 million adults Treatment-resistant share: nearly one-third Expected research effort: exceed $70 million +2 more

5 metrics

Adults affected more than 21 million adults United States each year

Treatment-resistant share nearly one-third of adults affected by major depressive disorder

Expected research effort exceed $70 million MAP-D initiative

Pilot phase funding $22 million three-year pilot phase

Pilot duration 3 years MAP-D pilot phase

Previous Partnership Reports

3 past events · Latest: Jul 01 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 01	Foundation partnership	Positive	+0.3%	Reaffirmed partnership with the National Medal of Honor Museum Foundation
May 26	Foundation partnership	Positive	+0.2%	Highlighted support for the Navy SEAL Foundation's Warrior Fitness Program
Sep 26	Industry partnership	Positive	-0.4%	Partnered with Eli Lilly on a new Gateway Labs location

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Partnership announcements produced mostly small positive reactions, with one negative divergence.

Key Terms

precision medicine, major depressive disorder, treatment-resistant depression, biological signatures

4 terms

precision medicine medical

"designed to redefine how major depressive disorder is diagnosed and treated through precision medicine."

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

major depressive disorder medical

"how major depressive disorder is diagnosed and treated through precision medicine."

A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.

treatment-resistant depression medical

"nearly one-third of whom suffer from treatment-resistant depression"

A form of major depression that does not improve after a person has tried standard treatments such as common antidepressant medications and therapy; think of it as a stubborn problem that doesn’t respond to the usual fixes. It matters to investors because it represents a large unmet medical need and a higher-risk, higher-reward area for drug developers, with potential for premium pricing, regulatory scrutiny, and durable demand if an effective new therapy is approved.

biological signatures medical

"identify and validate biological signatures of depression"

A set of measurable biological features—such as genes, proteins, metabolites, cell types, or imaging patterns—that together indicate a disease state, a response to treatment, or a biological process. Think of them as biological fingerprints that help detect, classify, or track conditions the way a weather pattern signals a storm. They matter to investors because companies that discover, validate, or commercialize reliable signatures can drive diagnostic tests, targeted therapies, clinical trial success, and regulatory outcomes that influence revenue and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PASADENA, Calif, July 29, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation clusters, today announced with the Foundation for the National Institutes of Health (FNIH) that the Multi-Modal Assessment and Phenotyping in Depression (MAP-D) initiative has successfully completed its critical design phase, marking a foundational milestone toward a first-of-its-kind clinical study designed to redefine how major depressive disorder is diagnosed and treated through precision medicine. Launched with Alexandria's vision and first funding, and founded on its strategic partnership with the FNIH, MAP-D seeks to identify and validate biological signatures of depression that can enable more personalized treatment approaches, accelerate the development of more effective therapies and ultimately improve outcomes for millions of patients.

"Major depressive disorder affects more than 21 million adults in the United States each year, nearly one-third of whom suffer from treatment-resistant depression," said Lynne Zydowsky, PhD, chief of science at Alexandria Real Estate Equities, Inc./Alexandria Venture Investments. "For too long, depression has been diagnosed primarily through symptoms and treated as a single disease, despite the biological differences that exist from one patient to another and the frequent overlap with related conditions such as PTSD. We are proud to partner with the FNIH to advance a transformative precision medicine framework that has the potential to fundamentally improve how depression is understood, diagnosed and treated."

Alexandria is the FNIH's founding strategic partner, providing the initial catalytic funding and securing the strategic cross-sector support required to establish the public-private partnership and launch the MAP-D initiative. In 2025, the FNIH honored Alexandria with the prestigious Charles A. Sanders, MD, Partnership Award in recognition of the company's extraordinary contributions to accelerating biomedical innovation, exemplified by Alexandria's leadership in advancing this highly consequential initiative.

Completion of the MAP-D design phase establishes the scientific framework for a long-term clinical study that aims to generate one of the most comprehensive depression research datasets ever assembled. As announced today by the FNIH, the initiative is advancing toward a research effort expected to exceed $70 million, beginning with a $22 million, three-year pilot phase. The study will leverage advanced artificial intelligence models to identify relationships between biological markers and patient outcomes. Ultimately, MAP-D seeks to establish biologically informed subtypes of depression, enable more precise treatment selection and accelerate the development of new therapies. Among its critical objectives, the public-private partnership will strive to make its data broadly accessible to qualified researchers, foster transparency, accelerate scientific discovery and extend the benefits of its precision medicine framework to other serious mental illnesses. To learn more about the MAP-D initiative and its partners, please visit fnih.org/our-programs/multi-modal-assessment-phenotyping-depression.

About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500^® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. For more information, please visit www.are.com.

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the anticipated funding, timing, launch, scope, duration, enrollment, expansion and conduct of the MAP-D initiative and its pilot phase; the use of artificial intelligence and other data-analysis methods in the initiative; the initiative's ability to identify and validate biological signatures of depression, inform more personalized treatment approaches, accelerate the development of more effective therapies and improve patient outcomes; and Alexandria's role in and support of the initiative, its collaboration with the FNIH and the anticipated impact and benefits of such support and collaboration. These forward-looking statements are based on Alexandria's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the availability and timing of funding; the receipt of required approvals; participant recruitment and retention; the performance of collaborators; scientific, technical and operational challenges; and changes in the initiative's design, scope, timing or cost, as well as the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update or revise any forward-looking statement, except as required by law. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q. 

CONTACT: Sara Cohen, Assistant Vice President – Capital Markets & Corporate Operations, (646) 799-2617, scohen@are.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-announces-foundational-milestone-in-mission-critical-partnership-with-the-foundation-for-the-national-institutes-of-health-to-advance-precision-medicine-for-depression-302837078.html

SOURCE Alexandria Real Estate Equities, Inc.

FAQ

What did Alexandria Real Estate Equities (NYSE: ARE) announce about the MAP-D depression initiative on July 29, 2026?

Alexandria Real Estate Equities announced that the MAP-D depression initiative completed its critical design phase, establishing the framework for a long-term precision medicine clinical study. According to Alexandria, the program targets better diagnosis and treatment of major depressive disorder using biological signatures and advanced data analytics.

What is the MAP-D initiative in Alexandria Real Estate Equities’ partnership with FNIH for depression research?

MAP-D is a precision medicine initiative focused on major depressive disorder, developed through Alexandria’s strategic partnership with FNIH. According to Alexandria, it aims to identify and validate biological signatures of depression to enable more personalized treatments and support development of more effective therapies over time.

How much funding is expected for the MAP-D depression study linked to Alexandria Real Estate Equities (ARE)?

The MAP-D research effort is expected to exceed $70 million, beginning with a $22 million, three-year pilot phase. According to Alexandria, this funding will support comprehensive data collection, advanced artificial intelligence analyses, and broad data access for qualified researchers in depression research.

How will the MAP-D study use artificial intelligence in depression research backed by Alexandria Real Estate Equities?

The MAP-D study plans to use advanced artificial intelligence models to analyze relationships between biological markers and patient outcomes. According to Alexandria, these AI tools are intended to help define biologically informed depression subtypes and support more precise treatment selection for major depressive disorder.

What role does Alexandria Real Estate Equities (NYSE: ARE) play in the FNIH MAP-D public-private partnership?

Alexandria is described as FNIH’s founding strategic partner for MAP-D, providing initial catalytic funding and cross-sector support. According to Alexandria, this role helped establish the public-private partnership, launch the initiative, and advance its precision medicine framework for depression and related serious mental illnesses.

How could the MAP-D initiative impact future treatments for major depressive disorder?

MAP-D aims to establish biologically informed subtypes of depression and enable more precise treatment selection. According to Alexandria, the initiative also seeks to accelerate development of new therapies by creating a large, comprehensive dataset and making it broadly accessible to qualified researchers worldwide.